Details

Autor(en) / Beteiligte

• Kluger, G.
• Glauser, T.
• Krauss, G.
• Seeruthun, R.
• Perdomo, C.
• Arroyo, S.

Titel

Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study

Ist Teil von

• Acta neurologica Scandinavica, 2010-09, Vol.122 (3), p.202-208

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in Lennox‐Gastaut syndrome: a long‐term, open‐label extension study.
Acta Neurol Scand: 122: 202–208.
© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard. Objective –  This open‐label extension evaluated the long‐term efficacy and tolerability of rufinamide in patients with Lennox‐Gastaut syndrome (LGS) who had previously completed a 12‐week double‐blind study. Materials and methods –  In total, 124 patients (aged 4–37 years), receiving 1–3 concomitant antiepileptic drugs, were treated with rufinamide ∼25–60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests. Results –  Overall, patients were treated with rufinamide for a median (range) of 432 (10–1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had ≥50% reduction in total and tonic–atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%). Conclusions –  In this open‐label extension, rufinamide appeared to be an effective long‐term adjunctive therapy for the treatment of LGS‐associated seizures in children and young adults.